MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesSimplywall·Aug 16 at 10:56 AMMDWD+0.72%
Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and Capricor Therapeutics (CAPR)businessinsider·Aug 15 at 07:31 PMCAPR-7.97%MDWD+0.72%
MediWound (MDWD) Q2 2026 Earnings Call: VALU on Track, Guidance ReaffirmedTradingKey·Aug 14 at 03:28 AMMDWD+0.72%VCEL+1.35%
MDWD: Q2 revenue fell, but guidance held as EscharEx and NexoBrid programs advanced and U.S. sales grewQuartr·Aug 13 at 07:13 AMMDWD+0.72%VCEL+1.35%
MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic woundsQuartr·Aug 13 at 06:06 AMMDWD+0.72%
MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharExPUBT·Aug 13 at 06:06 AMMDWD+0.72%
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateUnusual Whales·Aug 13 at 06:06 AMMDWD+0.72%
MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 millionPUBT·Aug 13 at 06:06 AMMDWD+0.72%
MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200-Day Moving Average - Here's What HappenedMarket Beat·Aug 6 at 04:00 AMMDWD+0.72%
